AbbVie Inc.

146.38+1.81+1.25%Vol 4.78M1Y Perf -11.70%
Dec 6th, 2023 16:00 DELAYED
BID144.88 ASK147.20
Open144.79 Previous Close144.57
Pre-Market- After-Market146.38
 - -  - -%
Target Price
164.57 
Analyst Rating
Moderate Buy 1.97
Potential %
12.43 
Finscreener Ranking
     40.48
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     41.70
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     54.16
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★+     35.16
Price Range Ratio 52W %
41.51 
Earnings Rating
Strong Buy
Market Cap258.44B 
Earnings Date
27th Oct 2023
Alpha0.01 Standard Deviation0.07
Beta0.48 

Today's Price Range

144.73147.07

52W Range

130.96168.11

5 Year PE Ratio Range

189.90781.90

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
2.80%
1 Month
2.97%
3 Months
-1.70%
6 Months
7.24%
1 Year
-11.70%
3 Years
38.30%
5 Years
68.33%
10 Years
203.94%

TickerPriceChg.Chg.%
ABBV146.381.81001.25
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
0.70
0.90
0.79
4.35
7.60
Leverage Ratio 9.10
ProfitabilityValueIndustryS&P 500US Markets
69.60
29.40
43.80
17.30
21.83
RevenueValueIndustryS&P 500US Markets
42.93B
24.28
20.25
16.25
DividendsValueIndustryS&P 500US Markets
3.66
5.92
8.98
17.50
Payout ratio134.00
Earnings HistoryEstimateReportedSurprise %
Q03 20232.862.953.15
Q02 20232.792.914.30
Q01 20232.442.460.82
Q04 20223.543.601.69
Q03 20223.563.662.81
Q02 20223.423.512.63
Q01 20223.153.160.32
Q04 20213.293.310.61
Earnings Per EndEstimateRevision %Trend
12/2023 QR2.923.55Positive
12/2023 FY11.241.90Positive
3/2024 QR2.4210.50Positive
12/2024 FY11.161.00Positive
Next Report Date-
Estimated EPS Next Report2.85
Estimates Count7
EPS Growth Next 5 Years %5.00
Volume Overview
Volume4.78M
Shares Outstanding1.77M
Shares Float1.77B
Trades Count67.79K
Dollar Volume698.96M
Avg. Volume4.91M
Avg. Weekly Volume5.09M
Avg. Monthly Volume5.03M
Avg. Quarterly Volume4.62M

AbbVie Inc. (NYSE: ABBV) stock closed at 146.38 per share at the end of the most recent trading day (a 1.25% change compared to the prior day closing price) with a volume of 4.78M shares and market capitalization of 258.44B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 50000 people. AbbVie Inc. CEO is Richard A. Gonzalez.

The one-year performance of AbbVie Inc. stock is -11.7%, while year-to-date (YTD) performance is -9.42%. ABBV stock has a five-year performance of 68.33%. Its 52-week range is between 130.9601 and 168.11, which gives ABBV stock a 52-week price range ratio of 41.51%

AbbVie Inc. currently has a PE ratio of 355.80, a price-to-book (PB) ratio of 18.42, a price-to-sale (PS) ratio of 6.66, a price to cashflow ratio of 13.10, a PEG ratio of 71.16, a ROA of 9.98%, a ROC of 17.00% and a ROE of 97.14%. The company’s profit margin is 21.83%, its EBITDA margin is 43.80%, and its revenue ttm is $42.93 Billion , which makes it $24.28 revenue per share.

Of the last four earnings reports from AbbVie Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.85 for the next earnings report. AbbVie Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.97), with a target price of $164.57, which is +12.43% compared to the current price. The earnings rating for AbbVie Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AbbVie Inc. has a dividend yield of 3.66% with a dividend per share of $5.92 and a payout ratio of 134.00%.

AbbVie Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.39, ATR14 : 2.38, CCI20 : 145.74, Chaikin Money Flow : 0.11, MACD : -0.24, Money Flow Index : 57.33, ROC : 4.55, RSI : 61.43, STOCH (14,3) : 89.99, STOCH RSI : 1.00, UO : 62.20, Williams %R : -10.01), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Azita Saleki-Gerhardt (Option Excercise at a value of $1 285 500), Azita Saleki-Gerhardt (Sold 25 000 shares of value $3 738 143 ), Carrie C. Strom (Option Excercise at a value of $872 949), Carrie C. Strom (Sold 28 541 shares of value $4 310 770 ), Elaine K. Sorg (Option Excercise at a value of $3 025 487), Elaine K. Sorg (Sold 30 323 shares of value $4 714 887 ), Jeffrey Ryan Stewart (Option Excercise at a value of $1 196 496), Jeffrey Ryan Stewart (Sold 53 125 shares of value $8 089 998 ), Perry C. Siatis (Option Excercise at a value of $1 061 372), Perry C. Siatis (Sold 10 884 shares of value $1 675 378 ), Richmond Timothy (Option Excercise at a value of $2 324 418), Richmond Timothy (Sold 86 511 shares of value $13 691 164 ), Roxanne S. Austin (Sold 10 000 shares of value $1 505 000 ), Saleki-Gerhardt Azita (Option Excercise at a value of $2 673 325), Saleki-Gerhardt Azita (Sold 61 990 shares of value $9 452 358 ), Scott T. Reents (Sold 15 942 shares of value $2 440 354 ), Sorg Elaine (Option Excercise at a value of $2 805 467), Sorg Elaine (Sold 58 955 shares of value $9 264 140 ), Stewart Jeffrey (Option Excercise at a value of $1 196 496), Stewart Jeffrey (Sold 53 125 shares of value $8 089 998 ), Strom Carrie (Option Excercise at a value of $872 949), Strom Carrie (Sold 28 541 shares of value $4 310 770 ), Timothy J. Richmond (Option Excercise at a value of $2 324 418), Timothy J. Richmond (Sold 42 370 shares of value $6 925 018 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (44.44 %)
8 (47.06 %)
7 (43.75 %)
Moderate Buy
2 (11.11 %)
2 (11.76 %)
1 (6.25 %)
Hold
8 (44.44 %)
7 (41.18 %)
8 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.97
Moderate Buy
1.91
Moderate Buy
2.03

AbbVie Inc.

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

CEO: Richard A. Gonzalez

Telephone: +1 847 932-7900

Address: 1 North Waukegan Road, North Chicago 60064-6400, IL, US

Number of employees: 50 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

 

TipRanks News for ABBV


News

Stocktwits